Clinical Trial: Targeting ANKRD11 Reverses HBV-Specific CD8+ T Cell Dysfunction and Tolerance

U.S., Aug. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07777250) titled 'Targeting ANKRD11 Reverses HBV-Specific CD8+ T Cell Dysfunction and Tolerance' on Aug. 17.

Brief Summary: Achieving a functional cure for chronic hepatitis B (CHB) is largely hindered by the irreversible functional exhaustion and immune tolerance of hepatitis B virus (HBV)-specific CD8+ T cells. In our previous studies, an in vivo CRISPR screen identified ANKRD11 for the first time as an "epigenetic brake" on CD8+ T-cell effector function. Loss of ANKRD11 markedly enhanced the expansion, effector function, and viral clearance capacity of HBV-specific T cells. Based on these findings, we hypothesize that ANKRD11 regulates the epigene...